Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances and an increased risk for thyroid cancer, according to a study published in eBioMedicine.
Researchers at Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center uncovered racial bias leading to recommended therapy being rejected and to delays in care, diagnosis.
Cedars-Sinai Cancer investigators have identified two new treatment options for men with recurrent prostate cancer—both of which helped patients live longer without their disease progressing than the current standard treatment.
The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy.
In the phase III CheckMate-77T trial evaluating the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage 2A to 3B non-small cell lung cancer, the perioperative regimen showed a statistically significant and clinically meaningful improvement in the primary efficacy endpoint of event-free survival as assessed by Blinded Independent Central Review compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.
A Corewell Health study suggests that men who have longer prostatic urethras, the part of the urethra that travels through the prostate, may be at a higher risk of experiencing moderate, often chronic urinary side effects after receiving radiation for prostate cancer.
A collaborative team led by University of Cincinnati, University of North Carolina, and Duke University researchers intends to study the prevalence of stroke in patients with different cancer types.
Researchers at University of California San Diego have discovered a process in which liver cells share molecules via vesicle exchange in order to multiply under conditions that would ordinarily suppress cell proliferation. They also found evidence that this process occurs in various types of cancer cells, paving the way for a new approach to tackling treatment resistance in cancer.
The Society for Immunotherapy of Cancer and the International Bladder Cancer Group published bladder cancer clinical trial design recommendations, which provide a detailed clinical trial design guide to maximize the chance of capturing the benefit of medical therapies for each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer to metastatic disease.
